Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT05208905
Registration number
NCT05208905
Ethics application status
Date submitted
13/01/2022
Date registered
26/01/2022
Date last updated
24/01/2024
Titles & IDs
Public title
LIFE-BTK PK Sub-study
Query!
Scientific title
LIFE-BTK Pharmacokinetics (PK) Sub-study
Query!
Secondary ID [1]
0
0
ABT-CIP-10293 Ver. B
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Critical Limb Ischemia (CLI)
0
0
Query!
Condition category
Condition code
Cardiovascular
0
0
0
0
Query!
Other cardiovascular diseases
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Devices - Esprit BTK Device
Experimental: Esprit BTK - Participants who receives Esprit BTK device will be included in this arm
Treatment: Devices: Esprit BTK Device
Participants will receive Esprit BTK Device
Query!
Intervention code [1]
0
0
Treatment: Devices
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Time of Maximum (Tmax)
Query!
Assessment method [1]
0
0
Time to reach the maximal observed blood analyte concentration during the 60 day period of the study after assessing at different time frames (0 minute,10 minutes, 30 minutes, 1 hr, 2 hrs, 4 hrs, 6 hrs , 12 hrs, 1 day, 2 days, 3 days, 4 days, 5 days, 7 days, 14 days, 30 days and 60 days post implantation).
Query!
Timepoint [1]
0
0
0 to 60 days
Query!
Primary outcome [2]
0
0
Maximum Concentration (Cmax)
Query!
Assessment method [2]
0
0
Maximal observed blood analyte concentration. Cmax is the highest blood everolimus concentration reached during the 60 day period of the study after assessing at different time frames (0 minute, 10 minutes, 30 minutes, 1 hr, 2 hrs, 4 hrs, 6 hrs , 12 hrs, 1 day, 2 days, 3 days, 4 days, 5 days, 7 days, 14 days, 30 days and 60 days post implantation).
Query!
Timepoint [2]
0
0
0 to 60 days
Query!
Primary outcome [3]
0
0
AUC0-24h
Query!
Assessment method [3]
0
0
Area under the blood analyte concentration vs. time curve from time 0 up to 24 hours post Esprit BTK implantation. Calculated by the Lin Up Log Down trapezoidal method.
Query!
Timepoint [3]
0
0
0 to 24 hours
Query!
Primary outcome [4]
0
0
AUC Last/AUC0-t
Query!
Assessment method [4]
0
0
Area under the blood analyte concentration vs. time curve from time 0 up to the last quantifiable concentration reached during the 60 day period of the study. After assessing at different time frames (0 minute, 10 minutes, 30 minutes, 1 hr, 2 hrs, 4 hrs, 6 hrs , 12 hrs, 1 day, 2 days, 3 days, 4 days, 5 days, 7 days, 14 days, 30 days and 60 days post implantation). Calculated by the Lin Up Log Down trapezoidal method.
Query!
Timepoint [4]
0
0
0 to 60 days
Query!
Primary outcome [5]
0
0
AUC 0-infinity
Query!
Assessment method [5]
0
0
Area under the blood analyte concentration vs. time curve from time zero and extrapolated to infinite time, reached during the 60 day period of the study. After assessing at different time frames (0 minute, 10 minutes, 30 minutes, 1 hr, 2 hrs, 4 hrs, 6 hrs , 12 hrs, 1 day, 2 days, 3 days, 4 days, 5 days, 7 days, 14 days, 30 days and 60 days post implantation).
calculated as: AUC0-8 = AUClast + (Clast/?z)
The percentage of AUC0-8 obtained by extrapolation (%AUC0-8ex) is calculated as:
%AUC0-8ex = (AUC0-8 - AUClast)/ AUC0-8 * 100
Query!
Timepoint [5]
0
0
0 to 60 days
Query!
Primary outcome [6]
0
0
Terminal Elimination Rate Constant (?z)
Query!
Assessment method [6]
0
0
The apparent terminal elimination rate constant during the 60 day period of the study. After assessing at different time frames (0 minute, 10 minutes, 30 minutes, 1 hr, 2 hrs, 4 hrs, 6 hrs , 12 hrs, 1 day, 2 days, 3 days, 4 days, 5 days, 7 days, 14 days, 30 days and 60 days post implantation). Determined by linear regression of terminal points of the ln-linear analyte concentration-time curve.
Query!
Timepoint [6]
0
0
0 to 60 days
Query!
Primary outcome [7]
0
0
Terminal Elimination Half-life (t1/2term)
Query!
Assessment method [7]
0
0
The apparent terminal elimination half-life, reached during the 60 day period of the study. After assessing at different time frames (0 minute, 10 minutes, 30 minutes, 1 hr, 2 hrs, 4 hrs, 6 hrs , 12 hrs, 1 day, 2 days, 3 days, 4 days, 5 days, 7 days, 14 days, 30 days and 60 days post implantation).
calculated as: t1/2term = 0.693/?z.
Query!
Timepoint [7]
0
0
0 to 60 days
Query!
Primary outcome [8]
0
0
Drug Clearance (CL)
Query!
Assessment method [8]
0
0
The systemic drug clearance, reached during the 60 day period of the study. After assessing at different time frames (0 minute, 10 minutes, 30 minutes, 1 hr, 2 hrs, 4 hrs, 6 hrs , 12 hrs, 1 day, 2 days, 3 days, 4 days, 5 days, 7 days, 14 days, 30 days and 60 days post implantation).
Calculated as: CL = Dose/AUC0 - 8 .
Query!
Timepoint [8]
0
0
0 to 60 days
Query!
Eligibility
Key inclusion criteria
General
1. Subject must provide written informed consent prior to any clinical investigation
related procedure
2. Subject has symptomatic Critical Limb Ischemia (CLI), Rutherford Becker Clinical
Category 4 or 5
3. Subject requires primary treatment of one or more de novo or restenotic (treated with
prior PTA) infrapopliteal lesions
4. Subject must be at least 18 years of age
5. Female subject of childbearing potential should not be pregnant and must be on birth
control Note: Female subjects of child-bearing potential must have a negative
pregnancy test done within 7 days prior to the index procedure per site standard test.
Anatomic
1. One or more native infrapopliteal lesions, including de novo lesions in the same limb.
Restenotic (from prior PTA) lesions are allowed.
1. Lesion must be located in the proximal 2/3 of native infrapopliteal vessels, with
vessel diameter of = 2.5 mm and = 4.00 mm by investigator visual assessment.
2. Total scaffold length to completely cover/treat target lesion(s) must be between
170 and 256 mm (maximum total everolimus drug dose of 2714 µg).
3. The target vessel can have any other angiographic significant lesions (=50%) that
should be treated per institution standard of care prior to treatment of the
target lesion.
4. Tandem lesions are allowed and the total scaffold length used to cover the entire
diseased segment must be = 256 mm.
2. Target lesion(s) must have = 70% stenosis, per visual assessment at the time of the
procedure. If needed, quantitative imaging (angiography, IVUS, and/or OCT) can be used
to aid accurate sizing of the vessels.
3. The distal margin of the scaffold must be located = 10 cm proximal to the proximal
margin of the ankle mortise. If the vessel segment distal to the target lesion has a
significant lesion (> 50% stenosis), it should be treated per institution standard of
care prior to deployment of the scaffold.
4. Significant lesion (= 50% stenosis) in the inflow artery(ies) must be treated
successfully (as per physician's assessment of the angiography) through standard of
care prior to the treatment of the target lesion. Treatment must be done within the
same trial procedure. Treatment allowed for inflow artery lesions are PTA,
atherectomy, cutting/scoring balloon, Shockwave balloon, bare metal stent,
drug-eluting stents or drug-coated balloon. Everolimus-coated or eluting devices are
not allowed.
5. It is acceptable for non-target lesion(s) (if applicable) to be located in the same
infrapopliteal vessel(s) as the target lesion, and suitable to be treated per
institution standard of care. Non-target lesions must be treated successfully prior to
target lesions and not requiring re-cross of the scaffold.
6. Crossing of the target lesion in an antegrade fashion is preferred, but retrograde
crossing may be used. However, the treatment must be delivered antegrade.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
General
1. Subject is currently participating in another clinical investigation that has not yet
completed its primary endpoint.
2. Pregnant or nursing subjects and those who plan pregnancy during the clinical
investigation follow-up period.
3. Presence of other anatomic or comorbid conditions, or other medical, social, or
psychological conditions that, in the investigator's opinion, could limit the
subject's ability to participate in the clinical investigation or to comply with
follow-up requirements.
4. Incapacitated individuals, defined as persons who are mentally ill, mentally
handicapped, or individuals without legal authority, are excluded from the study
population.
5. Subject has had any amputation to the ipsilateral extremity other than the toe or
forefoot, or subject has had major amputation to the contralateral extremity < 1 year
prior to index procedure and is not independently ambulating.
6. Subject has known hypersensitivity or contraindication to device material and its
degradants (everolimus, poly (L-lactide), poly (DL-lactide), lactide, lactic acid) and
cobalt, chromium, nickel, platinum, tungsten, acrylic and fluoro polymers that cannot
be adequately pre-medicated. Subject has a known contrast sensitivity that cannot be
adequately pre-medicated.
7. Subject has known allergic reaction, hypersensitivity or contraindication to aspirin;
or to ADP antagonists such clopidogrel, prasugrel or ticagrelor; or to anticoagulants
such as heparin or bivalirudin, and therefore cannot be adequately treated with study
medications. Subject with planned surgery or procedure necessitating discontinuation
of antiplatelet medications, within 12 months after index procedure. Planned
amputation that will necessitate discontinuation of antiplatelet medications is
allowed.
8. Subject has life expectancy = 1 year.
9. Subject has had a stroke within the previous 3 months with residual Rankin score of =
2.
10. Subject has renal insufficiency as defined as an estimated GFR < 30 ml/min per
1.73m^2.
11. Subject is currently on dialysis.
12. Subject has platelet count < 100,000 cells/mm^3 or > 700,000 cells/mm^3, a WBC < 3,000
cells/mm^3, or hemoglobin < 9.0 g/dl.
13. Subject has known serious immunosuppressive disease (e.g., human immunodeficiency
virus), or has severe autoimmune disease, that requires chronic immunosuppressive
therapy (e.g., systemic lupus erythematosus, etc.), or subject is receiving
immunosuppression therapy for other conditions. Subjects treated for HIV (Human
Immunodeficiency Virus) and who have undetectable viral load, such that their immune
system is not considered compromised, are eligible.
14. Subject has Body Mass Index (BMI) <18.
15. Subject is receiving or scheduled to receive anticancer therapy for malignancy within
6 months prior to index procedure or within 1 year after the procedure. Patients
taking medications classified as chemotherapy but who have been in remission for at
least 6 months are eligible.
16. Subject has coagulation disorder that increases the risk of arterial thrombosis.
Subjects with deep vein thrombosis and disorders that increase the risk of deep vein
thrombosis can be included in the study.
17. Subject who requires thrombolysis as a primary treatment modality or requires other
treatment for acute limb ischemia of the target limb.
18. Subject has previously had, or requires surgical revascularization involving any
vessel of the ipsilateral extremity. Prior femoropopliteal or aortobifemoral bypass is
allowed. Any bypass to the tibial arteries is not allowed.
19. Subject has signs or symptoms of advanced limb infection or septicemia (fever > 38.5,
WBC > 15,000 cells/microliter, hypotension) at the time of assessment. Osteomyelitis
of the phalanges or metatarsal heads (as described in exclusion criteria #21a) or
cellulitis of the foot amenable to treatment with IV antibiotics at the time of
revascularization is acceptable.
20. Subject is bedridden or unable to walk (with assistance is acceptable). Subjects in
wheelchair who are able to mobilize on their own can be enrolled.
21. Subject with extensive tissue loss salvageable only with complex foot reconstruction
or non-traditional transmetatarsal amputations. This includes subjects with:
1. Osteomyelitis that extends proximal to the metatarsal heads. Osteomyelitis
limited to the phalanges or metatarsal heads is acceptable for enrollment.
2. Gangrene involving the plantar skin of the forefoot, midfoot, or heel
3. Deep ulcer or large shallow ulcer (> 3 cm) involving the plantar skin of the
forefoot, midfoot, or heel
4. Full thickness heel ulcer with/without calcaneal involvement
5. Any wound with calcaneal bone involvement
6. Wounds that are deemed to be neuropathic or non-ischemic in nature
7. Wounds that would require flap coverage or complex wound management for large
soft tissue defect
8. Full thickness wounds on the dorsum of the foot with exposed tendon or bone.
22. Subject is unable or unwilling to provide written consent prior to enrollment
23. Subject has active symptoms and/or a positive test result of COVID-19 or other rapidly
spreading novel infectious agent within the prior 2 months
Anatomic
1. Lesions with severe calcification, in which there is a high likelihood that successful
pre-dilatation cannot be achieved.
2. Lesion that has prior metallic stent implant.
3. Coronary or peripheral artery treated with everolimus-eluting device during index
procedure, or within 90 days prior to index procedure.
4. Target or (if applicable) non-target vessel contains visible thrombus as indicated in
the angiographic images.
5. Subject has angiographic evidence of thromboembolism or atheroembolism in the
ipsilateral extremity. (Pre- and post-angiographic imaging must confirm the absence of
emboli in the distal anatomy.)
6. Unsuccessfully treated proximal inflow limiting arterial stenosis or inflow-limiting
arterial lesions left untreated.
7. No angiographic evidence of a patent pedal artery.
8. Target or (if applicable) non-target lesion location requiring bifurcation treatment
method that requires scaffolding of both branches (provisional treatment, without
intention of scaffolding both branches is acceptable).
9. Aneurysm in the iliac, common femoral, superficial femoral, popliteal or target artery
of the ipsilateral extremity.
10. Visual assessment of the target lesion suggests that the investigator is unable to
pre-dilate the lesion according to the vessel diameter.
11. Target lesion has a high probability that atherectomy will be required at the time of
index procedure for treatment of the target vessel.
Note: staged procedures are not allowed in LIFE-BTK PK sub-study.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
N/A
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Not Applicable
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Active, not recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
10/02/2022
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
22/02/2028
Query!
Actual
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
9
Query!
Recruitment in Australia
Recruitment state(s)
WAU
Query!
Recruitment hospital [1]
0
0
Sir Charles Gairdner Hospital - Nedlands
Query!
Recruitment postcode(s) [1]
0
0
- Nedlands
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Florida
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Massachusetts
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Oklahoma
Query!
Country [4]
0
0
Taiwan
Query!
State/province [4]
0
0
Taipei
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Abbott Medical Devices
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
LIFE-BTK PK is a prospective, single-arm, open-label, non-blinded, non-randomized sub-study
of LIFE-BTK Randomized Controlled Trial (NCT04227899), that will enroll approximately 7
subjects in the United States (US) and outside the US with a maximum of 5 sites in the US. Of
the 7 subjects planned to be enrolled, 4 subjects will be treated with Esprit BTK in below
the knee artery(ies) in whom drug-coated balloons (DCB) were not used; 3 subjects will be
treated with Esprit BTK in below the knee artery(ies) in whom DCB were used for treatment of
inflow disease.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT05208905
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT05208905
Download to PDF